NCT01484678 is a clinical trial in Duchenne Muscular Dystrophy, sponsored by University of Florida.

Who is sponsoring NCT01484678?

NCT01484678 is sponsored by University of Florida.

What condition does NCT01484678 study?

NCT01484678 studies Duchenne Muscular Dystrophy, Becker Muscular Dystrophy.

Is NCT01484678 still recruiting?

NCT01484678 is currently recruiting now. Last updated 15 October 2025.

Last reviewed 2025-10-15 · How we verify

NCT01484678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

Recruiting now Last updated 15 October 2025

What this trial tests

trial in Duchenne Muscular Dystrophy in 550 participants. Currently enrolling.

Timeline

1 September 2020

Primary endpoint
31 August 2026

31 August 2026

Quick facts

Lead sponsor	University of Florida
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	550
Start date	1 September 2020
Primary completion	31 August 2026
Estimated completion	31 August 2026
Sites	3 locations across United States

Conditions studied

Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
Becker Muscular Dystrophy — all drugs for Becker Muscular Dystrophy →

Sponsor

University of Florida

Who can join

Adults 5 to 62, male only, with Duchenne Muscular Dystrophy or Becker Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Muscular Dystrophy (MD). The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with DMD with muscles of healthy individuals of the same age and monitor disease progression in those with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements. Additionally, the investigators will map the progression of Becker MD following adults with this rare disease. The primary objective is to conduct a multi-centered study to validate the potential of non-invasive magnetic resonance imaging and magnetic resonance spectroscopy to monitor disease progression and to serve as a noninvasive surrogate outcome measure for clinical trials in DMD and BMD. The secondary objective is to characterize the progressive involvement of the lower extremity, upper extremity, trunk/respiratory muscles in boys/men with DMD and BMD guiding clinical trials.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.
Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, et al · · 2016 · cited 140× · PMID 26891991 · DOI 10.1002/ana.24599
Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.
Arpan I, Willcocks RJ, Forbes SC, Finkel RS, et al · · 2014 · cited 122× · PMID 25098537 · DOI 10.1212/wnl.0000000000000775
MR biomarkers predict clinical function in Duchenne muscular dystrophy.
Barnard AM, Willcocks RJ, Triplett WT, Forbes SC, et al · · 2020 · cited 74× · PMID 32024675 · DOI 10.1212/wnl.0000000000009012
Modeling disease trajectory in Duchenne muscular dystrophy.
Rooney WD, Berlow YA, Triplett WT, Forbes SC, et al · · 2020 · cited 64× · PMID 32184340 · DOI 10.1212/wnl.0000000000009244
Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
Arora H, Willcocks RJ, Lott DJ, Harrington AT, et al · · 2018 · cited 58× · PMID 29742798 · DOI 10.1002/mus.26161
Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy.
Barnard AM, Willcocks RJ, Finanger EL, Daniels MJ, et al · · 2018 · cited 54× · PMID 29554116 · DOI 10.1371/journal.pone.0194283
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.
Goemans N, Signorovitch J, Sajeev G, Yao Z, et al · · 2020 · cited 29× · PMID 32611643 · DOI 10.1212/wnl.0000000000010170
Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy.
Willcocks RJ, Forbes SC, Walter GA, Sweeney L, et al · · 2021 · cited 16× · PMID 33394000 · DOI 10.1001/jamanetworkopen.2020.31851

Verify or expand the search:

Other recruiting trials for Duchenne Muscular Dystrophy

Currently open trials in the same condition.

NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
NCT06817382 — A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Ma · Phase 1 · recruiting
NCT06402942 — Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy · NA · recruiting
NCT06450639 — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) · Phase 2 · active not recruiting
NCT06692426 — Trial of Cell Based Therapy for DMD · Phase 1 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01484678 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 15 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01484678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing